Professional Animal Model Services

 

 

Client: A pharmaceutical company developing a new antibody targeting the IL-25 pathway for the treatment of AD 

 

Objective: To establish the efficacy and safety of the new anti-IL-25 antibody in preclinical models of atopic dermatitis, compared to a standard positive drug control.

 

Study: Efficacy study of mesenchymal stem cells for Acute Respiratory Distress Syndrome (ARDS).

 

Study Design: This study requires special attention to the transport, storage, revival, and cell status prior to administration of the investigational product. The experimental design includes low, medium, and high dosage groups of the investigational product, as well as normal and model control groups. Finally, detection parameters are designed based on the characteristic indicators of the disease.

 

Study：Several ADCs are being evaluated in preclinical efficacy trials. 

 

Study Design: Different animal models of autoimmune diseases have been chosen based on the various targets of the different ADCs, including rodents and non-human primates. The indications involved are psoriasis (pso), inflammatory bowel disease (IBD), systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and rheumatoid arthritis (RA). Different species, strains, and types of animal models are used for different indications in order to conduct efficacy trials. Various control drugs are selected for different models, different doses are designed to achieve the goals of the efficacy trials.

 

Study: Efficacy study of compound in appropriate neurologically related autoimmune diseases.. 

 

Study Design: Understanding that the client's compound targets mitochondrial damage-related autophagy and has neuro regenerative properties. Thorough understanding of the pathogenesis of multiple sclerosis, with a focus on autoimmune-mediated neuroinflammation and demyelination. Choice of an EAE model that best mimics the key features of multiple sclerosis, allowing for the assessment of the client's compound under relevant pathological conditions. Dosage and Administration Design: Development of a dosing regimen tailored to the compound's mechanism of action, ensuring optimal exposure to the target tissue at the appropriate time points during disease progression.

 

Study：Validation of antibody expression for various mRNA vaccines. 

 

Study Design: Injection of different types and concentrations of mRNA vaccines in different groups of non-human primates, with blood collection at different time points; detection of the expression of immune cells in blood at different time points using flow cytometry; development of antibody detection methods to assess antibody expression in serum.

 

Study: Efficacy study of gut microbiota supplying samples on MC903-induced AD model.

 

Study Design: Selection of appropriate routes of administration, induction methods, mouse strains based on the characteristics of the supplying samples. Designing varying concentrations of the supplying samples and choosing suitable evaluation methods for determining efficacy.